Lv1
30 积分 2024-04-21 加入
Mesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy
9天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
8个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
8个月前
已完结
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy
8个月前
已关闭
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
8个月前
已完结
#2043 Telitacicept in patients with IgA nephropathy
8个月前
已关闭
Comparative Efficacy and Safety of New Therapies for IgA Nephropathy: A Systematic Review and Network Meta-Analysis
8个月前
已关闭
皖公网安备34019202002308
